Insider buying last 90 days
No open-market insider purchases were filed for QGEN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Qiagen's quarterly results dominate the week's news, with net income for the three months ended 30 September 2026 falling 19% to USD 105.66 million even as net sales rose, alongside more than double the prior restructuring and acquisition expenses. Separately, the company reported choosing Medrio EDC for its in vitro diagnostic studies, and shareholders approved Jonathan M. Pratt as Managing Director following his move into the CEO role on 1 September 2026. Several voting rights disclosures from MFS, JPMorgan and Bank of America also surfaced this week as background filings.
Qiagen shares closed at $50.55, up 0.4%, sitting above both the 50-day ($45.98) and 200-day ($42.53) moving averages, with the 50-day above the 200-day. The stock has gained 11.4% over one month, 18.5% over three months and 54.9% over six months, trading within a 52-week range of $32.53 to $57.82. The GekkoIndex reads 46, placing it in the Neutral zone, while the price sits 8.2% below the Gekko Fair Value of $55.05.
The next earnings date falls on 3 February 2027, 85 days out, placing it beyond a typical 20-trading-day holding window. Across the last 8 quarters, Qiagen has beaten estimates 5 times, with the most recent report on 4 November 2026 showing an EPS of $0.65 against an estimate of $0.63 and a 1% reaction. Seasonality from this point in the calendar has averaged a 4.9% move over the next 20 trading days across 5 years, with gains in 3 of them. No insider, Congress, or unusual options activity appears in the respective windows, though one trailblazer holder is recorded.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Qiagen scores 3 supportive, 2 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed0 headwinds
Above 50 and 200-day
Close $49.89 is above the 50-day ($46.50) and 200-day ($42.45) averages, and the 50-day is above the 200-day.
See the chart51.1, Neutral
Reading 51.1 is in the Neutral zone.
See the GekkoIndex4.6% below
Price is within 5% of Gekko Fair Value (4.6% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 80 days
Next report Feb 3, 2027, 80 days away — outside a typical 20-trading-day hold.
See earnings+6.3% on average
From this point in the calendar, the next 20 trading days averaged +6.3% over 5 years, rising in 5 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Qiagen closed at $49.89 on Nov 13, 2026, +12.0% over the past year, inside a 52-week range of $32.53 to $57.82.
Use the left and right arrow keys to read daily values.
Put QGEN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Qiagen focuses on converting raw biological specimens into readable molecular information for laboratories worldwide. It is known for kits and devices that isolate and purify DNA and RNA from samples, plus diagnostic consumables used in tuberculosis screening, monitoring transplant patients, prenatal checks, and identifying HPV and other sexually transmitted infections. Its catalog also includes PCR-based research products, tools for human identification and forensic work, and next-generation sequencing items like gene panels and library preparation reagents.
The business is built around three pillars: disposable consumables, laboratory instruments, and digital tools, giving customers both the reagents and the hardware needed to run tests, plus bioinformatics platforms and cloud-based software for analyzing outcomes. Buyers include diagnostic labs and life sciences researchers working across genomics, infectious disease detection, and forensic genealogy applications.
Qiagen traces back to 1984 and operates out of Venlo in the Netherlands. Its stock trades on the NYSE under the ticker QGEN.
Qiagen’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 51.1, in the Neutral zone, up 4.9 points over five sessions.
Up 4.9 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 65 | −0.6% | +2.9% | ||
| Accumulation | 205 | 0.0% | −0.5% | ||
| Neutral (current zone) | 399 | +0.6% | +1.3% | ||
| Distribution | 30 | −2.1% | −5.6% | ||
| Selling | 3 | Too few readings yet | |||
Average QGEN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Qiagen trades 4.6% below Gekko Fair Value of $52.28, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Qiagen shares are worth, recalculated every trading day.
$52.28
Gekko Fair Value, Nov 14, 2026
4.6% below fair value · About fair value
At the end of Aug 2026 the price was 17.1% below the estimate.
No open-market insider purchases were filed for Qiagen, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for QGEN in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in QGEN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Qiagen has been buying back its own shares.
From company filings.
1of the funds Gekko tracks holds QGEN.
Qiagen reports on Feb 3, 2027 (80 days away), and beat the EPS estimate in 5 of its last 8 reports.
Feb 3, 2027
80 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 4, 2026 | $0.65 est $0.63 | $548.0M est $538.6M | +1.0% |
| Aug 5, 2026 | $0.62 est $0.60 | $535.0M est $527.5M | −1.4% |
| May 6, 2026 | $0.54 est $0.54 | $492.3M est $496.1M | −1.4% |
| Feb 4, 2026 | $0.62 est $0.61 | $540.4M est $528.4M | −1.3% |
| Nov 4, 2025 | $0.64 est $0.61 | $532.6M est $525.9M | −3.6% |
| Aug 5, 2025 | $0.60 est $0.60 | $533.5M est $515.8M | −5.5% |
| May 7, 2025 | $0.55 est $0.50 | $483.5M est $468.9M | 0.0% |
| Feb 5, 2025 | $0.64 est $0.65 | $521.2M est $518.5M | −2.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Qiagen is $49.59, −0.6% from the last close, from 11 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 11 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 13 | UBS | $50 | +0.2% |
| Oct 27 | Barclays | $53 | +6.2% |
| Oct 26 | Citi | $52 | +4.2% |
| Oct 22 | Robert W. Baird | $52 | +4.2% |
| Oct 22 | J.P. Morgan | $52 | +4.2% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Qiagen averaged +6.3% across the last 5 years, rising in 5 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.4% | 4 of 5 |
| Next 10 trading days | +4.1% | 5 of 5 |
| Next 15 trading days | +2.7% | 5 of 5 |
| Next 20 trading days | +6.3% | 5 of 5 |
| Next 30 trading days | +6.4% | 5 of 5 |
For scale, QGEN’s typical 20-trading-day move in either direction is about 4.5%.
Qiagen’s market cap is $10.30B, with a P/E ratio of 27.1 and revenue of $2.12B over the last twelve months.
Coverage of Qiagen this week reads neutral: 4 positive, 8 neutral and 1 negative headlines.
Qiagen’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 15.0% above |
| ABTAbbott Laboratories | Neutral | 10.5% below |
| DHRDanaher | Neutral | 4.7% above |
| ISRGIntuitive Surgical | Neutral | 17.5% above |
| MDTMedtronic | Neutral | 14.2% below |
| SYKStryker | Neutral | 0.1% below |
A peer links to its own page where one exists.
Qiagen’s market cap is $10.30B at the Nov 13, 2026 close of $49.89, with 206.5M shares outstanding. The shares trade on a P/E ratio of 27.1.
The consensus analyst 12-month price target for Qiagen is $49.59, −0.6% from the last close. Of the 11 firms that rated the stock in the last 90 days, 4 rate it a buy, 7 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Qiagen is about fair value: the Nov 13, 2026 close of $49.89 is 4.6% below Gekko Fair Value of $52.28. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Qiagen is expected to report on Feb 3, 2027 (80 days away). Analysts expect earnings of $0.66 per share on revenue of $573.2M. Qiagen beat the earnings estimate in 5 of its last 8 reports, moving 2% on average across the report.
Qiagen’s 52-week high is $57.82 and its 52-week low is $32.53; it closed at $49.89 on Nov 13, 2026, +12.0% over the past year. Over the last five years the shares peaked at $58.43 on Nov 26, 2021.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, earnings risk and seasonality), 2 as mixed (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.